- Home
- AMRN vs ALLO Comparison
AMRN vs ALLO Comparison
Compare AMRN & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- ALLO
- Stock Information
- Founded
- AMRN 1989
- ALLO 2017
- Country
- AMRN Ireland
- ALLO United States
- Employees
- AMRN N/A
- ALLO N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMRN Health Care
- ALLO Health Care
- Exchange
- AMRN Nasdaq
- ALLO Nasdaq
- Market Cap
- AMRN 302.0M
- ALLO 252.9M
- IPO Year
- AMRN 1993
- ALLO 2018
- Fundamental
- Price
- AMRN $16.29
- ALLO $1.24
- Analyst Decision
- AMRN Strong Sell
- ALLO Buy
- Analyst Count
- AMRN 1
- ALLO 12
- Target Price
- AMRN $12.00
- ALLO $8.80
- AVG Volume (30 Days)
- AMRN 155.4K
- ALLO 2.9M
- Earning Date
- AMRN 10-29-2025
- ALLO 11-06-2025
- Dividend Yield
- AMRN N/A
- ALLO N/A
- EPS Growth
- AMRN N/A
- ALLO N/A
- EPS
- AMRN N/A
- ALLO N/A
- Revenue
- AMRN $226,733,000.00
- ALLO N/A
- Revenue This Year
- AMRN N/A
- ALLO N/A
- Revenue Next Year
- AMRN N/A
- ALLO $100.00
- P/E Ratio
- AMRN N/A
- ALLO N/A
- Revenue Growth
- AMRN N/A
- ALLO N/A
- 52 Week Low
- AMRN $7.08
- ALLO $0.86
- 52 Week High
- AMRN $20.90
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- AMRN 35.29
- ALLO 49.56
- Support Level
- AMRN $19.39
- ALLO $1.21
- Resistance Level
- AMRN $20.90
- ALLO $1.31
- Average True Range (ATR)
- AMRN 1.04
- ALLO 0.07
- MACD
- AMRN -0.53
- ALLO -0.01
- Stochastic Oscillator
- AMRN 2.74
- ALLO 26.39
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.